Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Glomerulonephritis | Research

Clinicopathological characteristics and predictors of outcome of rapidly progressive glomerulonephritis: a retrospective study

Authors: Osama Nady Mohamed, Sharehan Abdelrahman Ibrahim, Rabeh Khairy Saleh, Ahmed S. Issa, Amr Setouhi, Ayman Ahmed Abd Rabou, Mahmoud Ragab Mohamed, Shaimaa F. Kamel

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

Globally, there are regional and time-based variations in the prevalence, etiology, and prognosis of rapidly progressive glomerulonephritis (RPGN). Prognosis of RPGN is poor, with a higher risk of death and end stage renal disease (ESRD) even with immunosuppressive medications. In the Middle East and North Africa, the studies on this disease are very limited. Therefore, we determined the predictors of outcome of RPGN.

Methods

We retrospectively assessed 101 adult patients over age of 18, diagnosed with RPGN based on renal biopsy illustrating crescents in ≥ 50% of the glomeruli. Patients who had crescents in their renal biopsies that were < 50% and those who refused to consent to a renal biopsy were excluded. We categorized the patients into 3 groups based on immunohistochemistry; type I, type II and type III. Then, depending on renal loss, we divided them into ESRD and non-ESRD groups. The clinical history and physical examination were retrieved. Additionally, 24-hour urine protein, urine analysis, renal function tests, serum albumin, complete blood count, antinuclear antibodies, anti-double stranded DNA antibodies, ANCA antibodies and serum complement levels were checked. Each patient underwent a kidney biopsy for immunohistochemistry and light microscopy. The percentage of crescentic glomeruli, number of sclerosed glomeruli, tertiary lymphoid organ (TLO), neutrophil infiltration, endocapillary or mesangial hypercellularity, interstitial fibrosis with tubular atrophy (IFTA) were analyzed. Primary outcomes (remission, ESRD and mortality) and secondary outcomes were assessed.

Results

Type II was the most frequent cause of RPGN (47.5%), followed by type III (32.7%) and type I (19.8%). 32 patients (31.7%) died during follow up, whereas 60 patients (59.4%) developed ESRD. In 41 patients (40.6%), remission occurred. Oliguria, serum creatinine, and need for HD at presentation were significantly increased in ESRD group compared to non-ESRD group (P < 0.001 for each). Mesangial proliferation, IFTA, TLO formation, sclerotic glomeruli and fibrous crescents were also significantly increased in ESRD group in comparison to non-ESRD group (P < 0.001 for each). Glomerulosclerosis (P = 0.036), and IFTA (P = 0.008) were predictors of ESRD. Infections (P = 0.02), respiratory failure (P < 0.001), and heart failure (P = 0.004) were mortality risk factors.

Conclusion

Type II RPGN was the most common. Infection was the most frequent secondary outcome. Oliguria, glomerulosclerosis, the requirement for hemodialysis at presentation, IFTA and TLO formation were predictors of ESRD. Respiratory failure, heart failure and infections were significant predictors of mortality.
Literature
1.
go back to reference Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274. Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.
2.
go back to reference Sharma D, Mehta S, Sandhu JS, Sohal PM, Makkar V. Clinicohistological Profile and outcomes of Rapidly Progressive Glomerulonephritis: a prospective study from North India. Saudi J Kidney Dis Transpl. 2022;33(1):122–31.PubMed Sharma D, Mehta S, Sandhu JS, Sohal PM, Makkar V. Clinicohistological Profile and outcomes of Rapidly Progressive Glomerulonephritis: a prospective study from North India. Saudi J Kidney Dis Transpl. 2022;33(1):122–31.PubMed
3.
go back to reference Alexander S, Yusuf S, Rajan G, John EE, Roy S, Annamalai V et al. Crescentic glomerulonephritis: what’s different in South Asia? A single center observational cohort study. Wellcome Open Res. 2020;5. Alexander S, Yusuf S, Rajan G, John EE, Roy S, Annamalai V et al. Crescentic glomerulonephritis: what’s different in South Asia? A single center observational cohort study. Wellcome Open Res. 2020;5.
4.
go back to reference Mosaad FG, Saggaf OM, Aletwady KT, Jan KYM, Al-Qarni KA, Al-Harbi RS, et al. Assessment of the etiologies and renal outcomes of rapidly progressive glomerulonephritis in pediatric patients at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Saudi Med J. 2018;39(4):354.CrossRefPubMedPubMedCentral Mosaad FG, Saggaf OM, Aletwady KT, Jan KYM, Al-Qarni KA, Al-Harbi RS, et al. Assessment of the etiologies and renal outcomes of rapidly progressive glomerulonephritis in pediatric patients at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Saudi Med J. 2018;39(4):354.CrossRefPubMedPubMedCentral
5.
go back to reference Wangnoo A, Banotra P, Bali S. Study of the Clinical Profile of Rapidly Progressive Glomerulonephritis. Int J Res Rev. 2020;7(4):286–94. Wangnoo A, Banotra P, Bali S. Study of the Clinical Profile of Rapidly Progressive Glomerulonephritis. Int J Res Rev. 2020;7(4):286–94.
6.
go back to reference Nagaraju SP, Laxminarayana SLK, Kosuru S, Parthasarathy R, Attur RP, Rangaswamy D, et al. Clinicopathological characteristics and outcomes of diffuse crescentic glomerulonephritis - A single Center experience from Southern India. J Clin Diagn Res. 2017;11(9):Oc21–oc24.PubMedPubMedCentral Nagaraju SP, Laxminarayana SLK, Kosuru S, Parthasarathy R, Attur RP, Rangaswamy D, et al. Clinicopathological characteristics and outcomes of diffuse crescentic glomerulonephritis - A single Center experience from Southern India. J Clin Diagn Res. 2017;11(9):Oc21–oc24.PubMedPubMedCentral
7.
go back to reference Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, et al. Etiology and outcome of crescentic glomerulonephritis from a single center in China: a 10-year review. Am J Kidney Dis. 2016;67(3):376–83.CrossRefPubMed Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, et al. Etiology and outcome of crescentic glomerulonephritis from a single center in China: a 10-year review. Am J Kidney Dis. 2016;67(3):376–83.CrossRefPubMed
8.
go back to reference Sinha A, Puri K, Hari P, Dinda AK, Bagga A. Etiology and outcome of crescentic glomerulonephritis. Indian Pediatr. 2013;50:283–8.CrossRefPubMed Sinha A, Puri K, Hari P, Dinda AK, Bagga A. Etiology and outcome of crescentic glomerulonephritis. Indian Pediatr. 2013;50:283–8.CrossRefPubMed
9.
go back to reference Gupta R, Singh L, Sharma A, Bagga A, Agarwal SK, Dinda AK. Crescentic glomerulonephritis: a clinical and histomorphological analysis of 46 cases. Indian J Pathol Microbiol. 2011;54(3):497.CrossRefPubMed Gupta R, Singh L, Sharma A, Bagga A, Agarwal SK, Dinda AK. Crescentic glomerulonephritis: a clinical and histomorphological analysis of 46 cases. Indian J Pathol Microbiol. 2011;54(3):497.CrossRefPubMed
10.
go back to reference Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, et al. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019;18(5):3984–90.PubMedPubMedCentral Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, et al. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019;18(5):3984–90.PubMedPubMedCentral
11.
go back to reference Faye M, Lemrabott AT, Fall K, Dial MMC, Cisse MM, El Boumaoui N et al. Crescentic glomerulonephritis in a sub-saharan country: clinical presentation, etiological and evolutive profile. Nephrourol Mon. 2017;9(6). Faye M, Lemrabott AT, Fall K, Dial MMC, Cisse MM, El Boumaoui N et al. Crescentic glomerulonephritis in a sub-saharan country: clinical presentation, etiological and evolutive profile. Nephrourol Mon. 2017;9(6).
12.
go back to reference Bjergfelt SS, Sørensen IMH, Hjortkjær H, Landler N, Ballegaard ELF, Biering-Sørensen T, et al. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification. PLoS ONE. 2021;16(11):e0260417.CrossRefPubMedPubMedCentral Bjergfelt SS, Sørensen IMH, Hjortkjær H, Landler N, Ballegaard ELF, Biering-Sørensen T, et al. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification. PLoS ONE. 2021;16(11):e0260417.CrossRefPubMedPubMedCentral
13.
go back to reference Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney int. 1999;55(2):713–23.CrossRefPubMed Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney int. 1999;55(2):713–23.CrossRefPubMed
14.
go back to reference Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186(3):1849–60.CrossRefPubMed Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186(3):1849–60.CrossRefPubMed
16.
go back to reference Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014;13(7):723–9.CrossRefPubMed Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014;13(7):723–9.CrossRefPubMed
17.
go back to reference Han F, Chen L, Le J, Choong P, Xu Y, Wang H, et al. The clinicopathologic spectrum of rapidly progressive glomerulonephritis based on glomerular immune deposition and antineutrophil cytoplasmic antibody. Appl Immunohistochem Mol Morphol. 2015;23(10):704–10.CrossRefPubMed Han F, Chen L, Le J, Choong P, Xu Y, Wang H, et al. The clinicopathologic spectrum of rapidly progressive glomerulonephritis based on glomerular immune deposition and antineutrophil cytoplasmic antibody. Appl Immunohistochem Mol Morphol. 2015;23(10):704–10.CrossRefPubMed
18.
go back to reference Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20(3):322–41.CrossRefPubMedPubMedCentral Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20(3):322–41.CrossRefPubMedPubMedCentral
19.
go back to reference Rampelli S, Rajesh N, Srinivas B, Kumar KH, Swaminathan R, Priyamvada P. Clinical spectrum and outcomes of crescentic glomerulonephritis: a single center experience. Indian J Nephrol. 2016;26(4):252.CrossRefPubMedPubMedCentral Rampelli S, Rajesh N, Srinivas B, Kumar KH, Swaminathan R, Priyamvada P. Clinical spectrum and outcomes of crescentic glomerulonephritis: a single center experience. Indian J Nephrol. 2016;26(4):252.CrossRefPubMedPubMedCentral
20.
go back to reference Al-Hussain T, Asiri S, Amer S, Al Mana H, Akhtar M. Patterns of glomerulonephritis with crescents: experience at a tertiary medical center in Saudi Arabia. Saudi J Kidney Dis Transpl. 2017;28(3):532–7.CrossRefPubMed Al-Hussain T, Asiri S, Amer S, Al Mana H, Akhtar M. Patterns of glomerulonephritis with crescents: experience at a tertiary medical center in Saudi Arabia. Saudi J Kidney Dis Transpl. 2017;28(3):532–7.CrossRefPubMed
21.
go back to reference Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed
22.
go back to reference Quiroga B, Vega A, Rivera F, López-Gómez J, Glomerulonephritis. SRo. Crescentic glomerulonephritis: data from the S panish G lomerulonephritis R egistry. Intern Med J. 2015;45(5):557–762. Quiroga B, Vega A, Rivera F, López-Gómez J, Glomerulonephritis. SRo. Crescentic glomerulonephritis: data from the S panish G lomerulonephritis R egistry. Intern Med J. 2015;45(5):557–762.
23.
go back to reference Parry MA, Mazumder MA, Sharma M, Jeelani H, Alam S. Clinicopathological spectrum and outcome of Crescentic Glomerulonephritis: a retrospective study from North-East India. J Ren Hepatic Disorders. 2022;6(1):24–31.CrossRef Parry MA, Mazumder MA, Sharma M, Jeelani H, Alam S. Clinicopathological spectrum and outcome of Crescentic Glomerulonephritis: a retrospective study from North-East India. J Ren Hepatic Disorders. 2022;6(1):24–31.CrossRef
24.
go back to reference Eksin MA, Oğuz EG, Atılgan KG, Şahin H, Selen T, Okyay GU, et al. Clinicopathological features and kidney survival in Rapidly Progressive Glomerulonephritis: a single-center experience. Turk J Nephrol. 2022;31(2):138–47.CrossRef Eksin MA, Oğuz EG, Atılgan KG, Şahin H, Selen T, Okyay GU, et al. Clinicopathological features and kidney survival in Rapidly Progressive Glomerulonephritis: a single-center experience. Turk J Nephrol. 2022;31(2):138–47.CrossRef
25.
go back to reference Lin W, Chen M, Cui Z, Zhao M-H. The immunopathological spectrum of crescentic glomerulonephritis: a survey of 106 patients in a single Chinese center. Nephron Clin Pract. 2010;116(1):c65–c74.CrossRefPubMed Lin W, Chen M, Cui Z, Zhao M-H. The immunopathological spectrum of crescentic glomerulonephritis: a survey of 106 patients in a single Chinese center. Nephron Clin Pract. 2010;116(1):c65–c74.CrossRefPubMed
26.
go back to reference Oudah N, Al Duhailib Z, Alsaad K, Qurashi S, Ghamdi G, Flaiw A, et al. Glomerulonephritis with crescents among adult Saudi patients outcome and its predictors. Clin Exp Nephrol. 2012;12:121–5. Oudah N, Al Duhailib Z, Alsaad K, Qurashi S, Ghamdi G, Flaiw A, et al. Glomerulonephritis with crescents among adult Saudi patients outcome and its predictors. Clin Exp Nephrol. 2012;12:121–5.
27.
go back to reference Ganesan V, Gurusamy V. A study of clinicopathological features and outcomes of crescentic glomerulonephritis. Int J Res Med 2020;Sci 8(3): 915–20. Ganesan V, Gurusamy V. A study of clinicopathological features and outcomes of crescentic glomerulonephritis. Int J Res Med 2020;Sci 8(3): 915–20.
29.
go back to reference Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody–associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139–60.CrossRefPubMedPubMedCentral Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody–associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139–60.CrossRefPubMedPubMedCentral
30.
go back to reference Sadioglu ERDOGMUSS, Kumru RE, Eyupoglu G, Kutlay S, Keven S. SAT-410 clinicopathologic features and outcomes of patients with crescentic glomerulonephritis with renal involvement: a Single-Center, 13-year Retrospective Study from Turkey. Kidney Int Rep. 2020;5(3):171.CrossRef Sadioglu ERDOGMUSS, Kumru RE, Eyupoglu G, Kutlay S, Keven S. SAT-410 clinicopathologic features and outcomes of patients with crescentic glomerulonephritis with renal involvement: a Single-Center, 13-year Retrospective Study from Turkey. Kidney Int Rep. 2020;5(3):171.CrossRef
31.
go back to reference Alsuheili AZ, Alhozali H, Bukhari AA, Khan MA, Alzahrani AS, Abualnaja SK et al. Clinico-pathological outcomes of patients with Crescentic Glomerulonephritis: a single-center study. Cureus. 2023;15(5). Alsuheili AZ, Alhozali H, Bukhari AA, Khan MA, Alzahrani AS, Abualnaja SK et al. Clinico-pathological outcomes of patients with Crescentic Glomerulonephritis: a single-center study. Cureus. 2023;15(5).
32.
go back to reference Sandhu J, MON-044 PREDICTION, OF OUTCOMES OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS. Kidney Int Rep. 2019;4(7):322. Sandhu J, MON-044 PREDICTION, OF OUTCOMES OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS. Kidney Int Rep. 2019;4(7):322.
33.
go back to reference Lim JH, Han MH, Kim YJ, Jeon Y, Jung HY, Choi JY, et al. Novel histopathologic predictors for renal outcomes in crescentic glomerulonephritis. PLoS ONE. 2020;15(7):e0236051.CrossRefPubMedPubMedCentral Lim JH, Han MH, Kim YJ, Jeon Y, Jung HY, Choi JY, et al. Novel histopathologic predictors for renal outcomes in crescentic glomerulonephritis. PLoS ONE. 2020;15(7):e0236051.CrossRefPubMedPubMedCentral
34.
go back to reference Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6(3):205–17.CrossRefPubMed Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6(3):205–17.CrossRefPubMed
35.
go back to reference Kapitsinou PP, Ioannidis JP, Boletis JN, Sotsiou F, Nakopoulou L, Daphnis E, et al. Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis. 2003;41(1):29–37.CrossRefPubMed Kapitsinou PP, Ioannidis JP, Boletis JN, Sotsiou F, Nakopoulou L, Daphnis E, et al. Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis. 2003;41(1):29–37.CrossRefPubMed
36.
go back to reference Aksoy A, McDonald S, Mccarthy E, Parker B, Bruce IN, AB0474 MORTALITY ACROSS RITUXIMAB-TREATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP (BILAG) REGISTRY. BMJ Publishing Group Ltd; 2019. Aksoy A, McDonald S, Mccarthy E, Parker B, Bruce IN, AB0474 MORTALITY ACROSS RITUXIMAB-TREATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP (BILAG) REGISTRY. BMJ Publishing Group Ltd; 2019.
37.
go back to reference Barmettler S, Ong M-S, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. AMA Netw Open. 2018;1(7):e184169–e.CrossRef Barmettler S, Ong M-S, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. AMA Netw Open. 2018;1(7):e184169–e.CrossRef
38.
go back to reference Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol: CJASN. 2014;9(5):905.CrossRefPubMedPubMedCentral Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol: CJASN. 2014;9(5):905.CrossRefPubMedPubMedCentral
39.
go back to reference Day CJ, Howie AJ, Nightingale P, Shabir S, Adu D, Savage CO, et al. Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine. Am J Kidney Dis. 2010;55(2):250–8.CrossRefPubMedPubMedCentral Day CJ, Howie AJ, Nightingale P, Shabir S, Adu D, Savage CO, et al. Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine. Am J Kidney Dis. 2010;55(2):250–8.CrossRefPubMedPubMedCentral
40.
go back to reference Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis. Ann Intern Med. 2005;143(9):621–31.CrossRefPubMed Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis. Ann Intern Med. 2005;143(9):621–31.CrossRefPubMed
41.
go back to reference Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S, et al. Short-term effectiveness and safety of Rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis. 2024;83(1):103–11.CrossRefPubMed Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S, et al. Short-term effectiveness and safety of Rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis. 2024;83(1):103–11.CrossRefPubMed
42.
go back to reference Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.CrossRefPubMed Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.CrossRefPubMed
Metadata
Title
Clinicopathological characteristics and predictors of outcome of rapidly progressive glomerulonephritis: a retrospective study
Authors
Osama Nady Mohamed
Sharehan Abdelrahman Ibrahim
Rabeh Khairy Saleh
Ahmed S. Issa
Amr Setouhi
Ayman Ahmed Abd Rabou
Mahmoud Ragab Mohamed
Shaimaa F. Kamel
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03532-y

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.